Please join #ACR20 for late breaking abstract on Ziritaxestat, selective autotaxin inhibitor. Phase 2a trial with stats significant effect on skin score and well tolerated. @UMIntMed Session Date Monday, November 9 Presentation Time: 12:15 PM - 12:30 PM ET

ILD in SSc has grave consequences. Abstr#393 Claims database in Ontario shows relevant Scleroderma ILD occurred in 17% of >3000 pts with nearly double the mortality #ACR20 @RheumNow @CRASCRRheum #bestinclass https://t.co/K3UXvuxBcp

Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/